News
IKT
2.430
-2.80%
-0.070
Inhibikase advances IKT-001 in pivotal PAH Phase 3
TipRanks · 1h ago
Weekly Report: what happened at IKT last week (0831-0904)?
Weekly Report · 1d ago
Monthly top ideas from Oppenheimer include MA, MRVL, CMG, and more
Seeking Alpha · 6d ago
Weekly Report: what happened at IKT last week (0824-0828)?
Weekly Report · 08/31 09:10
Weekly Report: what happened at IKT last week (0817-0821)?
Weekly Report · 08/24 09:11
Weekly Report: what happened at IKT last week (0810-0814)?
Weekly Report · 08/17 09:11
Analysts Are Bullish on Top Healthcare Stocks: Evotec AG (EVO), Taysha Gene Therapies (TSHA)
TipRanks · 08/14 15:30
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth
TipRanks · 08/13 06:01
Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Benzinga · 08/11 20:16
Press Release: Inhibikase Therapeutics Announces -2-
Dow Jones · 08/11 20:01
Press Release: Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Dow Jones · 08/11 20:01
Weekly Report: what happened at IKT last week (0803-0807)?
Weekly Report · 08/10 09:10
Weekly Report: what happened at IKT last week (0727-0731)?
Weekly Report · 08/03 09:10
Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
TipRanks · 07/31 10:45
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
TipRanks · 07/29 20:39
Analysts Are Bullish on These Healthcare Stocks: The Ensign Group (ENSG), Stryker (SYK)
TipRanks · 07/28 10:50
Weekly Report: what happened at IKT last week (0720-0724)?
Weekly Report · 07/27 09:11
Inhibikase Gains FDA Orphan Drug Status for IKT-001
TipRanks · 07/23 13:02
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
TipRanks · 07/23 12:16
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
Benzinga · 07/23 12:03
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).